Patients with refractory LCH typically exhibit characteristics such as age under 2 years, risk organ involvement, elevated inflammatory markers, and resistance to standard treatment and often harbor the BRAF V600E mutation [7]. Here, BRAF is linked to Langerhans cell histiocytosis.